INTrODuCTION. Stability of extemporaneous preparations has been of interest to compounding pharmacists since the use of finished products (tablets, capsules, injections) as a direct source of active pharmaceutical ingredients. Excipients of these finished products do not only alter the microbial stability of the compounded preparations but may cause non-uniform distribution and also degradation of the active component of interest, leading to actual loss in the claimed quantity of labelled dose. Verified assay method is pertinent to ascertain the uniformity of a compounded formulation [1] [2] [3] [4] [5] [6] [7] .
The British, European, Indian and Japanese pharmacopoeias recommend titrimetry for pure pharmaceutical substance and the uV-spectrophotometric assay methods for tablet and injection dosage forms. Taking into consideration that compounded syrups can be prepared using pure pharmaceutical substances or manufactured products (such as tablets, capsules etc) as active pharmaceutical ingredient [8] [9] [10] [11] , there is need to validate potential analytical methods that could be used for compounded syrups.
The purpose of our work is to validate an ultraviolet spectroscopic method for determining furosemide in such extemporaneous syrups. Hydrochlorico Extraca), uV-spectrophotometer (Thermoscientific Evolution 60S) with 10 mm quartz cells, mortar, pestle, analytical balance (aXIS, Poland alN220). all reagents and solvents meet and were prepared in accordance with the requirements of The State Pharmacopoeia of ukraine (SPu) which also agrees with the European Pharmacopoeia [14] .
compounding technology of Syrup: levigate accurately weighed 500 mg of furosemide substance (or equivalent quantity of powdered tablet mass) with a small portion of syrup to form a paste. add syrup gradually with stirring to form a homogenous mixture. Fill the mixture with the same base up to 100 ml to form a 5 mg/ml suspension.
Method: Weigh quantity of 5 mg/ml compounded suspension, equivalent to 50 mg of furosemide, on an analytical balance. Transfer the suspension into a 100 ml volumetric flask, add 10 ml of 0.1 M sodium hydroxide, shake and allow standing for 20 minutes. Dilute with the same solvent to 100 ml. Dilute 2 ml of the obtained solution to 100 ml with 0.1 M sodium hydroxide. Measure the absorbance at 271 nm using 0.1 M sodium hydroxide as the compensation solution.
Calculate the content of C 12 H 11 C l N 2 O 5 S taking 580 as the value of a (1 %, 1 cm) as the maximum at 271 nm using the formula:
where a 1 -observed absorbance,
A nom
-specific 0.01 g/l solution, D -dilution of analysed sample, C s -final concentration (mg/ml) of analysed solution, m t -mass of analyte.
rESulTS aND DISCuSSION. The validation criteria for tolerance content ±10 % were defined according to the requirements of SPu and the work on development and validation of quality assurance methods for compounded preparations [15] : range 80-120 %, permitted deviation in content (B, %) ±10 %, critical value of the error (maxΔ as ,%) 3.2 %, maximum systematic error (δ max ,%) 1.02 %, coefficient of determination (r 2 c ) 0.9924 , γ-intercept on the calibration graph (a, %) 4.7 %, uncertainty of absorbance (δ abs ,%) 2.43 %.
During method development 0.1 M sodium hydroxide was selected as solvent, based on pharmacopoeial recommendations [8] [9] [10] [11] ] on furosemide's solubility.
In the prognosis of the analytical method uncertainty, the maximum permissible errors during operations associated with use of glassware [14] and value of uncertainty in final analytical operation, Δ FaO (0.49) [15] were taken into consideration. The uncertainty of the method was found to be 0.72 %, which falls within specified limits Δ as ≤maxΔ as .
Specificity: Fig. 1 shows that neither sucrose nor the excipients in tablet significantly interfered with the result from spectrophotometric determination of furosemide.
also, a correspondence in peaks at wavelength 271 nm for both substance and tablets is seen, thus, the method is specific for furosemide. The influence of placebo (only syrup) was taken by repeating the procedure in the section method with just the dispersion vehicle. Its influence was calculated with the formula:
, where its absorbance, a blank =0.001; a st =0.580. Contribution of the placebo to the total absorbance of the analyte is 0.17 %. Its influence is within the limits of the criteria (≤δ max =1.7%, ≤δ abs =2.43).
The maximum uncertainty of absorbance for our preparations was calculated using the formula:
, where Δa -tolerance for absorbance, ±0.01 [9] .
Linearity and range. The absorbance samples was measured at a concentration range of 8×10 -3 -
1.2×10
-2 mg/ml, corresponding to 80-120 % nominal concentration of furosemide. The values in the linearity graphs were converted to nominal coordinates [15] . The linear graphs below show their corresponding linear dependence. The regression line equations obtained Y=1.04•X-3.99 and Y=0.96•X+3.42 for substance and tablets respectively suspended in syrup (Fig. 2, Table 1 ), in conformity with Beer-lambert's law. The coefficients of determination were ≥0.9981 for all samples.
Accuracy of the method (Table 1 ) was ascertained at 5 levels with 3 repetitions at each level. Quantity equivalent to 80 %, 90 %, 100 %, 110 % and 120 % was added to samples. The mean percentage recoveries of the substances as against theoretical values ranged between 98.41 to 101.20 % for furosemide substance and 98.20 to 99.68 % for furosemide tablet in syrup. The systematic errors (substance in syrup -0.08 %, tablets in syrup -0.86 %) indicate the accuracy of the method.
Precision: The absorbance of 10 µg/ml solutions from commercial tablets in syrup for two brands were observed at different times of the day (intraday) and on different days (interday) by different analysts ( Table 2 ). The cumulative relative standard deviation (rSD, %), which is a measure of precision, was 0.73. The method was found to be precise. robustness. Deliberate variations in wavelength and extraction time were made to show the reliability of the method. Syrups containing 50 mg of furosemide was shaken with 10 ml 0.1 M sodium hydroxide and were allowed to stand for 20, 40 and 60 minutes before further sample preparation procedures. The method was found to be robust (Table 3) .
Stability of analytical solutions of observed and found to be stable for 1 hour (Table 4) . Time zero minute is counted from the moment the final dilution is made. There was no significant change in pH or absorbance.
Metrological characteristics of the method do not exceed the critical value of the error (3.2 %) and are characterized by qualitative analytical indicators. This method can be correctly reproduced in the laboratory.
CONCluSIONS. a non-derivative uV-spectrophotometric method has been developed and validated for content determination of furosemide 
